August 9, 2013

Dear TB Controllers and Program Managers:

RE: Tubersol in limited supply

We have recently heard reports from a number of states regarding difficulty obtaining TUBERSOL. Below is updated information received from the Sanofi representative in California.

_TUBERSOL Diagnostic Antigen in the 50-test presentation is experiencing a supply interruption until Fall 2013 due to a temporary delay in production. As a result, increased demand has limited the availability of TUBERSOL Diagnostic Antigen in the 10-test presentation._

To allow us to continue to supply the market with product, we are placing allocations on customer orders which will go into effect immediately. Allocations will be based on a percentage of historical usage for customers who order an average of 10 doses or more per month, and these allocations are expected to be in effect until October. A follow-up communication will be sent in October when we expect to lift these allocations. (TUBERSOL® - Sanofi Pasteur Limited 1-800-822-2463).

The availability of the alternate product used for TB skin tests, APLISOL (APLISOL® - JHP Pharmaceuticals, LLC - 1-877-547-4547) may be affected by increased demand for this product. We will provide additional information and guidance as soon as it becomes available from the CDC and FDA.

If you experience any difficulty obtaining TUBERSOL, APLISOL, TB medications or experience a significant price increase in one of these products, please contact one of our nurse consultants (Lisa True or Gayle Schack) or the TB Branch medical officer on duty at (510) 620-3000. We continue to track these problems in order to inform our national partners.

Sincerely,

Jennifer Flood, M.D., M.P.H., Chief
Tuberculosis Control Branch
Division of Communicable Disease Control
Center for Infectious Diseases
California Department of Public Health